Sci Immunol. 2021 Aug 10;6(62). doi: 10.1126/sciimmunol.abf3733.
The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.
《COVID-19 队列中的免疫表型评估（IMPACC）》是一项前瞻性纵向研究，旨在招募 1000 名 COVID-19 住院患者（NCT04378777）。IMPACC 收集详细的临床、实验室和影像学数据，以及血液和呼吸道分泌物的纵向生物学样本，进行深入检测。临床和实验室数据进行整合，以确定与 COVID-19 易感性、严重程度和疾病进展相关的免疫学、病毒学、蛋白质组学、代谢组学和基因组学特征。IMPACC 的目标是更好地了解病原体动力学和宿主免疫反应对 COVID-19 的严重程度和病程的影响，并为鉴定生物标志物和有效治疗方法提出假设，包括此类干预的最佳时机。本报告总结了 IMPACC 研究设计和方案，包括临床标准和招募、多地点标准化样本采集和处理、病毒学和免疫学检测、检测方案的协调、高级分析和数据共享计划。
